Pituitary Gland Carcinoma
Associated Genetic Biomarkers
NCI Definition: A rare adenocarcinoma with poor prognosis, arising from the adenohypophysial cells of the anterior lobe of the pituitary gland or pre-existing adenomas. The majority are hormonally functioning neoplasms, usually producing prolactin or ACTH. The diagnosis is based on the presence of metastases. Syndromes associated with pituitary gland carcinomas include hyperprolactinemia, Cushing disease, and acromegaly. 
Pituitary gland carcinomas most frequently harbor alterations in WWTR1, TMPRSS2, STAG2, SPEN, and RNF43 .
WWTR1 Q232_Q233dup, TMPRSS2 G313R, STAG2fs, SPEN T2685I, and RNF43 R219C are the most common alterations in pituitary gland carcinoma .
There are 4 clinical trials for pituitary gland carcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain pituitary gland carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 3 are phase 2 (2 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for pituitary gland carcinoma clinical trials .
Afatinib, ipilimumab, and lutetium lu 177 dotatate are the most common interventions in pituitary gland carcinoma clinical trials.
Significant Genes in Pituitary Gland Carcinoma
EGFR is an inclusion eligibility criterion in 1 clinical trial for pituitary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pituitary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.